
US-based ADMA Biologics develops plasma biologics for treating and preventing infectious diseases.
Founded in Ramsey, United States, ADMA Biologics is dedicated to developing plasma-derived biologics aimed at treating and preventing infectious diseases. The company's core mission is to enhance the lives of immunocompromised individuals and patients at risk for certain infections through innovative immunotechnology. ADMA Biologics offers a portfolio of FDA-approved immune globulin products and utilizes a proprietary microneutralization assay to measure neutralizing antibody levels.
Notable figures associated with ADMA Biologics include experienced professionals in the biopharmaceutical industry and key investors who have supported its mission. The company has achieved significant milestones, including the approval and commercialization of its immune globulin products. ADMA Biologics' impact is evident in its contribution to improving patient outcomes and advancing the field of plasma-derived therapeutics.

Biomat USA
grifolsplasma.com

AIM Immunotech
aimimmuno.com

Adimab
adimab.com

MacroGenics
macrogenics.com

Adaptive Biotechnologies

ADS Biotechnology

Direct Biologics

Idbiologics
idbiologics.com

IGM Biosciences
igmbio.com

Circle Biologics

BioClonetics Immunotherapeutics

ProThera Biologics
Critical Biologics

HI-Bio
hibio.com

Whitehawk Therapeutics
aadibio.com
Companies similar to ADMA Biologics include Biomat USA, AIM Immunotech, Adimab and MacroGenics.
ADMA Biologics was founded in 2004.
ADMA Biologics' headquarters is located in Ramsey, NJ, US.
ADMA Biologics' most recent funding round was for $135M (USD) in December 2023.
As of Dec 18, 2023, ADMA Biologics has raised a total of $742.4M (USD).
ADMA Biologics has 617 employees as of Feb 6, 2024.